Abeona Therapeutics (ABEO) Trading Down 0.3%

Abeona Therapeutics Inc (NASDAQ:ABEO) shares traded down 0.3% during trading on Thursday . The company traded as low as $9.66 and last traded at $10.00. 22,180 shares were traded during mid-day trading, a decline of 98% from the average session volume of 888,127 shares. The stock had previously closed at $10.03.

A number of research analysts recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $36.00 price target on shares of Abeona Therapeutics in a research note on Saturday, August 11th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Abeona Therapeutics in a research note on Thursday, September 13th. ValuEngine downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. BidaskClub raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Finally, Zacks Investment Research downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. Abeona Therapeutics has an average rating of “Buy” and a consensus price target of $26.80.

The company has a market capitalization of $613.67 million, a P/E ratio of -15.80 and a beta of 1.10.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Friday, August 10th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.06). The business had revenue of $0.82 million for the quarter, compared to analyst estimates of $1.81 million. Abeona Therapeutics had a negative return on equity of 23.02% and a negative net margin of 881.74%. Research analysts anticipate that Abeona Therapeutics Inc will post -0.88 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Parkside Advisors LLC bought a new stake in shares of Abeona Therapeutics during the third quarter worth about $160,000. United Services Automobile Association bought a new stake in shares of Abeona Therapeutics during the second quarter worth about $162,000. Northern Trust Corp grew its holdings in shares of Abeona Therapeutics by 28.2% during the second quarter. Northern Trust Corp now owns 390,342 shares of the biopharmaceutical company’s stock worth $6,246,000 after purchasing an additional 85,908 shares during the last quarter. FMR LLC grew its holdings in shares of Abeona Therapeutics by 47.7% during the second quarter. FMR LLC now owns 7,094,307 shares of the biopharmaceutical company’s stock worth $113,509,000 after purchasing an additional 2,291,016 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in shares of Abeona Therapeutics by 120.3% during the second quarter. California Public Employees Retirement System now owns 55,508 shares of the biopharmaceutical company’s stock worth $888,000 after purchasing an additional 30,316 shares during the last quarter. 76.24% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile (NASDAQ:ABEO)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Story: How Short Selling Works

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply